Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HDM1002-301

HDM1002-301

HDM1002 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HDM1002
Population
obesity
Phase
3
Participants
857
Duration
52 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
200 mg QDobesity china52857−10.7 % vs −1.5 %
Δ −9.2 pp
−9.4 % vs −1.5 %
Δ −7.9 pp
—1.5 vs 0.6—————press release
400 mg QDobesity china52857−12.2 % vs −1.5 %
Δ −10.7 pp
−11.3 % vs −1.5 %
Δ −9.8 pp
—2.0 vs 0.6—————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (6)
  • 200 mg QD · weight_eff · HKEX filing
    第 52 周 -10.7% -12.2% -1.2%
  • 200 mg QD · weight_tp · HKEX filing
    第 52 周 -9.4% -11.3% -0.9%
  • 200 mg QD · ae_dc · 四、安全性 paragraph
    因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)
  • 400 mg QD · weight_eff · HKEX filing
    第 52 周 -10.7% -12.2% -1.2%
  • 400 mg QD · weight_tp · HKEX filing
    第 52 周 -9.4% -11.3% -0.9%
  • 400 mg QD · ae_dc · 四、安全性 paragraph
    因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HDM1002-301. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1002-301/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.